Course Description:
As researchers and manufacturers develop and produce vaccines to protect against COVID-19 and other infectious agents, it is critical to demonstrate the vaccines' quality, safety, and efficacy. In less than two years since the start of the devastating global pandemic caused by coronavirus SARS-CoV-2, scientists have developed over 300 candidate vaccines, and some received approval in less than a year. Significant advances in multiple manufacturing platforms and analytical technologies support the rapid pace of vaccine development. Some of the new COVID-19 vaccines have spurred the use of novel analytical technologies to support rapid and thorough characterization, which may help pave the way for other vaccine manufacturers to implement these technologies. Now more than ever, it is vital to develop and improve tests and analytical methods that ensure the quality of vaccines and maintain public trust.
Who should participate:
- QA Manager
- QA Staff
- QC Chemist
- QC Manager
- R&D
- Regulatory
- Student
The live version of this recording took place on March 7, 2022
Access Duration:
Access to this course expires 60 days from the date of registration or until you mark the course ‘Complete’ – whichever occurs first.
Speakers:
Earl Zablackis
Director-Principal Scientist at Sanofi Pasteur and Chair of the USP Biologics 3 Expert Committee for Complex Biologics & Vaccines
Sarita Acharya
Principal Scientist, Global Biologics, U.S. Pharmacopeia
Huijuan Li, Vice President
Analytical Development, Moderna and member of the USP Biologics 5 Expert Committee for Advanced Therapies
Mark van Ooij
Scientific Director, PER.C6 Technical Lead and Head of Platform Innovation and Implementation, Janssen and member of the USP Biologics 3 Expert Committee for Complex Biologics & Vaccines
Desmond Hunt
Senior Principal Scientist, Science-General Chapters, U.S. Pharmacopeia